ASPM Is a Prognostic Biomarker and Correlates With Immune Infiltration in Kidney Renal Clear Cell Carcinoma and Liver Hepatocellular Carcinoma

Deng, Tingting; Liu, Yang; Liu, Sian; Tang, Yizhe; Huo, Qin

doi:10.3389/fonc.2022.632042

Cited by 10 publications

(8 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vincent et al demonstrated that ASPM was an essential regulator of Wnt-Diseveled-3-β-catenin signaling and cancer stemness in prostate cancer, which can promote prostate cancer cells proliferation [ 35 ]. Another study identified that ASPM increased levels of immune cell infiltration in KIRC and LIHC [ 36 ]. Notably, enrichment analysis showed that NCAPD2 was associated with the Wnt signaling, which perhaps indicated NCAPD2 and ASPM may promote the development of various tumors immunity via Wnt signaling pathway.…”

Section: Discussionmentioning

confidence: 99%

NCAPD2 is a favorable predictor of prognostic and immunotherapeutic biomarker for multiple cancer types including lung cancer

Feng,

Yang,

Lin

et al. 2024

Genes and Environ

View full text Add to dashboard Cite

Background Non-SMC condensin I complex subunit D2 (NCAPD2) belongs to the chromosomal structural maintenance family. While the different contribution of NCAPD2 to chromosome in mitosis have been thoroughly investigated, much less is known about the expression of NCAPD2 in pan-cancer. Thus, we used a bioinformatics dataset to conduct a pan-cancer analysis of NCAPD2 to determine its regulatory role in tumors. Methods Multiple online databases were analyzed NCAPD2 gene expression, protein level, patient survival and functional enrichment in pan-cancer. Genetic alteration and tumor stemness of NCAPD2 were analyzed using cBioPortal and SangerBox. The GSCA and CellMiner were used to explore the relationship between NCAPD2 and drug sensitivity. The diagnostic value of prognosis was evaluated by ROC curve. Subsequently, the immune infiltration level and immune subtype of NCAPD2 in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) were analyzed using TIMER1 and TISIDB. Results NCAPD2 gene expression was significantly higher in most cancers and associated with clinical stage and poor prognosis. Genomic heterogeneity of NCAPD2 promoted the occurrence and development of tumors. GO enrichment analysis suggested NCAPD2 might be involved in DNA repair and immune response. NCAPD2 was involved in immune infiltration of LUAD and LUSC. ROC curves showed that NCAPD2 has important prognosis diagnostic value in LUAD and LUSC. Moreover, NCAPD2 was drug sensitive to topotecan, which may be an optimize immunotherapy. Conclusions It was found that NCAPD2 was overexpressed in pan-cancers, which was associated with poor outcomes. Importantly, NCAPD2 could be a diagnostic marker and an immune related biomarker for LUAD and LUSC.

show abstract

Section: Discussionmentioning

confidence: 99%

NCAPD2 is a favorable predictor of prognostic and immunotherapeutic biomarker for multiple cancer types including lung cancer

Feng,

Yang,

Lin

et al. 2024

Genes and Environ

View full text Add to dashboard Cite

show abstract

“…26 ASPM has also been shown to promote cancer progression. 27,28 TOP2A and CDNK3 have been screened to be involved in colorectal cancer progression. 29 Currently, TOP2 has been widely used in targeted therapy of cancers.…”

Section: Discussionmentioning

confidence: 99%

“…Chen et al identify 14 key genes related to the pathogenesis of colon cancer, including CEP55, TOP2A, RRM2, NCAPG2, providing new directions for elucidating the molecular mechanisms of colon cancer 26 . ASPM has also been shown to promote cancer progression 27,28 . TOP2A and CDNK3 have been screened to be involved in colorectal cancer progression 29 …”

Section: Discussionmentioning

confidence: 99%

Knockdown of TOP2A suppresses IL‐17 signaling pathway and alleviates the progression of ulcerative colitis

Li,

2024

Immunity Inflam & Disease

View full text Add to dashboard Cite

BackgroundUlcerative colitis (UC) is a chronic inflammatory disease of the colonic mucosa, with a gradually increasing incidence. Therefore, it is necessary to actively seek targets for the treatment of UC.MethodsCommon differentially expressed genes (DEGs) were screened from two microarray data sets related to UC. Protein−protein interaction network was constructed to find the hub genes. The UC mouse model and cell model were induced by dextran sulfate sodium (DSS). The pathological changes of colon tissue were observed by hematoxylin‐eosin staining. Immunohistochemistry and immunofluorescence were performed to detect the expressions of Ki67 and Claudin‐1. The performance of mice was observed by disease activity index (DAI). The effect of TOP2A on proliferation, inflammation, oxidative stress, and interleukin‐17 (IL‐17) signaling pathway in UC model was measured by cell counting kit‐8, enzyme‐linked immunosorbent assay, and western blot.ResultsThrough bioinformatics analysis, 295 common DEGs were screened, and the hub gene TOP2A was selected. In UC model, there was obvious inflammatory cell infiltration in the colon and less goblet cells, while si‐TOP2A lessened it. More Ki67 positive cells and less Claudin‐1 positive cells were observed in UC model mice. Furthermore, knockdown of TOP2A increased the body weight and colon length of UC mice, while the DAI was decreased. Through in vivo and in vitro experiments, knockdown of TOP2A also inhibited inflammation and IL‐17 signaling pathway, and promoted proliferation in DSS‐induced NCM460 cells.ConclusionKnockdown of TOP2A alleviated the progression of UC by suppressing inflammation and inhibited IL‐17 signaling pathway.

show abstract

“…ASPM, which is involved in mitotic spindle regulation and coordination of mitotic processes, has already been identified as a tumor marker in other settings. In an attempt to clarify the role of ASPM in tumor immunity and the prognosis of different cancers, Deng et al analyzed the expression of ASPM in different tissues including kidney renal clear cell carcinoma and liver hepatocellular carcinoma ( Deng et al, 2022 ). In these two types of cancers, higher expression of ASPM was evidenced in cancer tissues with respect to normal corresponding tissue, in late-stage cancers versus early-stage ones.…”

Section: Discussionmentioning

confidence: 99%

RNA-binding protein transcripts as potential biomarkers for detecting Primary Sclerosing Cholangitis and for predicting its progression to Cholangiocarcinoma

Ala,

Fagoonee

2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

Primary Sclerosing Cholangitis (PSC) is a persistent inflammatory liver condition that affects the bile ducts and is commonly diagnosed in young individuals. Despite efforts to incorporate various clinical, biochemical and molecular parameters for diagnosing PSC, it remains challenging, and no biomarkers characteristic of the disease have been identified hitherto. PSC is linked with an uncertain prognosis, and there is a pressing need to explore multiomics databases to establish a new biomarker panel for the early detection of PSC’s gradual progression into Cholangiocarcinoma (CCA) and for the development of effective therapeutic interventions. Apart from non-coding RNAs, other components of the Ribonucleoprotein (RNP) complex, such as RNA-Binding Proteins (RBPs), also hold great promise as biomarkers due to their versatile expression in pathological conditions. In the present review, an update on the RBP transcripts that show dysregulated expression in PSC and CCA is provided. Moreover, by utilizing a bioinformatic data mining approach, we give insight into those RBP transcripts that also exhibit differential expression in liver and gall bladder, as well as in body fluids, and are promising as biomarkers for diagnosing and predicting the prognosis of PSC. Expression data were bioinformatically extracted from public repositories usingTCGA Bile Duct Cancer dataset for CCA and specific NCBI GEO datasets for both PSC and CCA; more specifically, RBPs annotations were obtained from RBP World database. Interestingly, our comprehensive analysis shows an elevated expression of the non-canonical RBPs, FANCD2, as well as the microtubule dynamics regulator, ASPM, transcripts in the body fluids of patients with PSC and CCA compared with their respective controls, with the same trend in expression being observed in gall bladder and liver cancer tissues. Consequently, the manipulation of tissue expression of RBP transcripts might be considered as a strategy to mitigate the onset of CCA in PSC patients, and warrants further experimental investigation. The analysis performed herein may be helpful in the identification of non-invasive biomarkers for the early detection of PSC and for predicting its progression into CCA. In conclusion, future clinical research should investigate in more depth the full potential of RBP transcripts as biomarkers for human pathologies.

show abstract

ASPM Is a Prognostic Biomarker and Correlates With Immune Infiltration in Kidney Renal Clear Cell Carcinoma and Liver Hepatocellular Carcinoma

Cited by 10 publications

References 53 publications

NCAPD2 is a favorable predictor of prognostic and immunotherapeutic biomarker for multiple cancer types including lung cancer

NCAPD2 is a favorable predictor of prognostic and immunotherapeutic biomarker for multiple cancer types including lung cancer

Knockdown of TOP2A suppresses IL‐17 signaling pathway and alleviates the progression of ulcerative colitis

RNA-binding protein transcripts as potential biomarkers for detecting Primary Sclerosing Cholangitis and for predicting its progression to Cholangiocarcinoma

Contact Info

Product

Resources

About